Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Smb 25092014 jac wijkmans

595 views

Published on

  • Be the first to comment

  • Be the first to like this

Smb 25092014 jac wijkmans

  1. 1. Open Innovation in Small Molecule Lead Discovery “Center for Open Innovation in Drug Discovery” From Molecules to Business –25 September 2014 JacWijkmans
  2. 2. Take Home Messages Great need to organize pharma R&D in a different way Academia hold the key to bridge the innovation gap between exploratory research & early clinical development Merge the strengths of academic & industrial drug research Initiated a feasibility study to create “Center of Open Innovation in Drug Discovery” to place RU/Radboudumcat forefront of translational medicine Similar successful initiatives exist abroad that have proven to provide a sustainable academic drug discovery enterprise
  3. 3. The Pharma Landscape Society ‒Increasing incidence of chronic diseases. ‒Escalating health care costs ‒Increased patient awareness ‒Personalized health care Industry ‒Declining productivity ‒Risk aversion ‒R&D externalization ‒Late stage focus ‒Innovationpull ‒Driver: Shareholder value Academia ‒Austerity measures ‒Clinical trial experts ‒Increasingly entrepreneurial ‒Early stage focus ‒Valorizationpush ‒Driver: Publications & health
  4. 4. Evolving R&D Process <2005: The ‘good old days’ 2005 -present:Shift fromR&D toS&D (Search & Development) Industry Academia Pre-clinical candidate
  5. 5. Need to Organize Early R&D Differently Spin-off CRO #1 CRO #2 CRO #3 ? A: B: ‒Too early to out-license ‒Shortagein funds ‒Missing skills ‒No open innovation(recycling of knowledge, molecules, IP) Issues
  6. 6. Academia Hold the Key, however, … … while targets, assays, compound synthesis & patients are present, medicinal chemistry capabilities are critically missing Frye et al. Nature Rev. Drug Discov. 10, 2011, 409
  7. 7. Medicinal Chemistry Optimizing Molecular properties to get into Business Not acceptable Ideal 1. Affinity 2. Selectivity 3. Efficacy 4. Solubility 5. Metabolic Stability 6. Protein binding 7. Toxicity
  8. 8. Medicinal Chemistry Optimizing Molecularpropertiestoget intoBusiness Ideal Not acceptable 1. Affinity 2. Selectivity 3. Efficacy 4. Solubility 5. Metabolic Stability 6. Protein binding 7. Toxicity Multidimensional optimization paradigm
  9. 9. Empower Academic Drug Research Academic biomedical research Medicinal chemistry capabilities “Blend academic biomedical research with industry- standard drug discovery capabilities to valorize innovation” “Establish a leading force in academic drug discovery” Center for Open Innovation in Drug Discovery COIDD
  10. 10. Creating Value Chains
  11. 11. A Sustainable Pharma R&D Ecosystem IP (pre-)clinical candidates Platform technologies Spin-offs Publications Synergies/cross- overs Education & training $$$ $$$ Potential projects identified European Lead Factory HTS
  12. 12. Center forOpen Innovationin Drug Discovery (COIDD) Incorporate the highest level of drug discovery into academic research and advance the most exciting scientific breakthroughs towards the development of drug candidates suited for clinical studies Vision Establish an unique & sustainable pharmaceutical R&D ecosystem to create new small molecule therapeutics to improve public health and place RU/Radboudumcat forefront of translational medicine Mission
  13. 13. COIDD CoreExpertise MedicinalChemistry Chemical Biology Drug discovery Tool compounds Project Management & Development Leads & (pre)clinicalcandidates New projects industry-trained professionals Dedicated facilities
  14. 14. Open Innovation in Practice New molecular target or differentiating assay Clinical Need? amenable for HTS? HTS & compound optimization Pre-clinical candidate out- licensing/ partnership For example: Revolving funds
  15. 15. A Validated & Sustainable Model! “De-risking investments in new treatments for brain disorders by blending academic based research with state-of- the-art drug discovery resources” “Bringing dedicated medicinal chemistry expertise to bear on biological targets being investigated by UNC faculty”
  16. 16. A Validated & Sustainable Model! Vanderbilt Center for Neuroscience Drug Discovery Founded in 2003, Track Record: 2009:Drug discovery pact with J&J 2010:Research collaboration with Seaside Therapeutics 2011:Partnership Michael J. Fox Foundation 2011:License deal KarunaPharma 2012:BMS Parkinson R&D collaboration 2013:Licensing & research deal with AstraZeneca “De-risking investments in new treatments for brain disorders by blending academic based research with state-of- the-art drug discovery resources”
  17. 17. A Validated & Sustainable Model! “Exploiting and transforming innovative research into pharmaceutical applications in close cooperation with academic partners” Lead Discovery Centre Dortmund Founded in 2007, Track Record: 2011:First LDC lead licensed to Bayer 2013:2nd LDC lead licensed to Qurient Drug discovery alliance AstraZeneca Strategic partnership Merck Serono 2014:Drug discovery alliance Daiichi Sankyo
  18. 18. Embedding in Health Valley Region Radboud NanomedicineAlliance “HealthyBrain” Technology centers
  19. 19. Feasibility Study –Next Steps 1.Get buy in and commitment from major stakeholders 2.Determine focus, identify key partners, select projects 3.Learn from “best practices” 4.Further develop business plan (revenue model, financial requirements, organization, team) 5.Apply for grants, raise capital investments 6.Build team 3Q4Q1Q2Q3Q 2015 2014 preparation phase financing phase Go/NoGo Accelerate Project X Project Y Start
  20. 20. Conclusions Great need to organize pharma R&D in a different way Academia hold the key to bridge the innovation gap between exploratory research & early clinical development Merge the strengths of academic & industrial drug research The COIDD will place RU/Radboudumcat forefront of translational medicine Successful & sustainable precedents of COIDD exist but The Netherlands are falling behind … and we are determined to change this!
  21. 21. Initiators Prof. Floris Rutjes Dr. Thea van Kemenade Prof. Alain van Gool Dr. Pedro Hermkens Dr. JacWijkmans

×